On April 29, 2019, the Society for Cardiovascular Angiography and Interventions (SCAI) in concert with the American College of Cardiology (ACC), Society of Thoracic Surgeons (STS), and the American Association for Thoracic Surgery (AATS) submitted a letter asking the Centers for Medicare and Medicaid Services (CMS) to open the National Coverage Determination (NCD) for Transcatheter Mitral Valve Repair (TMVR) for reconsideration. Last month, Abbott garnered expanded indication for the MitraClip® TMVR system to treat patients with functional mitral regurgitation (MR). As the NCD is currently crafted and until it is revised, coverage for TMVR under the existing NCD is limited to only patients with degenerative MR. SCAI will continue to work closely with the multispecialty coalition to seek the alignment of coverage for TMVR with FDA approved indications supporting Medicare beneficiary access to TMVR.